Trikafta Exercise Study in Cystic Fibrosis
Long-term Effects of Elexacaftor/Tezacaftor/Ivacaftor (Trikafta) on Exertional Symptoms, Exercise Performance, Ventilatory Responses, and Body Composition in Adults With Cystic Fibrosis
University of British Columbia
20 participants
Nov 10, 2021
OBSERVATIONAL
Conditions
Summary
Shortness of breath (dyspnea) during exercise is a major source of distress and is a commonly reported symptom in patients with cystic fibrosis (CF). A recent drug treatment option known as Trikafta, which contains elexacaftor, tezacaftor, and ivacaftor, may be used in patients with CF to help improve lung health. However, the effects of this combination therapy on dyspnea and exercise performance, a known predictor of survival in CF, are not clear. The investigators aim to understand the effects of Trikafta on these symptoms and to gain new insight into the potential health improvements in CF from using this treatment option.
Eligibility
Inclusion Criteria9
- Confirmed diagnosis of CF and at least one copy of the F508del mutation in the cystic fibrosis transmembrane conductance regulator (CFTR) gene
- Plan to initiate Trikafta by the treating physician within 30 days of the enrolment visit
- Aged 19 years or older
- Stable clinical status based on clinical judgment of the treating physician
- Forced Expiratory Volume in 1 second (FEV1.0) < 90% predicted
- Body mass index greater than 16 or less than 30 kg/m\^2
- Currently non-smoking or a past smoking history of less than 20 pack-years
- Able to read and understand English
- Fully vaccinated (at least 2 doses) for Covid-19
Exclusion Criteria6
- A disease other than CF that could importantly contribute to dyspnea or exercise limitation
- Chronic airway infection with Mycobacterium abscessus, Burkholderia cepacia complex, or other organisms with infection control implications based on the treating physicians
- Contraindications to clinical exercise testing
- Use of supplemental oxygen or desaturation less than 85% with exercise
- Diagnosis of pneumothorax in the past 4 weeks
- History of organ transplantation
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
Elexacaftor/Tezacaftor/Ivacaftor combination therapy
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT05279040